Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

Delayed Quote. Delayed  - 05/27 05:35:05 pm
1452.5 GBp   -0.31%
05/27DJGLAXOSMITHKLINE : Says European Commission Approves Stem-Cell Therap..
05/27 GLAXOSMITHKLINE : StrimvelisTM receives European marketing authorisa..
05/27 GLAXOSMITHKLINE : Glaxo's Strimvelix Gene Therapy Gets European Mark..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M GBP Estimates in M GBP
Fiscal Period December 201320142015201620172018
Sales26 50523 00623 92325 53726 37927 525
Operating income (EBITDA)8 8838 0457 0288 4668 8859 288
Operating profit (EBIT)8 0156 5945 7296 7147 1247 641
Pre-Tax Profit (EBT)6 6472 96810 5264 3755 1426 011
Net income5 6282 7568 4222 7863 4194 231
P/E ratio0,150,240,0829,022,718,9
EPS (PNC )11156,717250,264,077,0
Dividend per Share (PNC )78,080,080,081,680,081,3
Yield484%581%583%5,62%5,51%5,60%
Reference price (PNC )16.113.813.71452.51452.51452.5
Announcement Date02/05/2014
12:00pm
02/04/2015
03:18pm
02/03/2016
12:00pm
---
Finances - Leverage
Actuals in M GBP Estimates in M GBP
Fiscal Period December 201320142015201620172018
Debt12 64514 37710 72712 63712 76612 349
Finance------
Operating income (EBITDA)8 8838 0457 0288 4668 8859 288
Leverage
(Debt/EBITDA)
1,42x1,79x1,53x1,49x1,44x1,33x
Capital Expenditure1 1881 1881 3801 7301 5271 478
Book Value Per Share (BVPS)146 PNC87,6 PNC106 PNC71,2 PNC68,8 PNC79,1 PNC
Cash Flow per Share149 PNC108 PNC53,2 PNC108 PNC127 PNC134 PNC
Announcement Date02/05/2014
12:00pm
02/04/2015
03:18pm
02/03/2016
12:00pm
---
Balance Sheet Analysis
Assessed data source :
© 2016 Thomson Reuters
Advertisement
Financial Ratios

Size 2016e 2017e
Capitalization 70 758 M GBP -
Entreprise Value (EV) 83 395 M GBP 83 524 M GBP
Valuation 2016e 2017e
P/E ratio (Price / EPS) 29,0x 22,7x
Capitalization / Revenue 2,77x 2,68x
EV / Revenue 3,27x 3,17x
EV / EBITDA 9,85x 9,40x
Yield (DPS / Price) 5,62% 5,51%
Price to book (Price / BVPS) 20,4x 21,1x
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) 26,3% 27,0%
operating Leverage (Delta EBIT / Delta Sales) 2,55x 1,86x
Net Margin (Net Profit / Revenue) 10,9% 13,0%
ROA (Net Profit / Asset) 7,20% 8,44%
ROE (Net Profit / Equities) 85,2% 116%
Rate of Dividend 163% 125%
Balance Sheet Analysis 2016e 2017e
CAPEX / Sales   6,78% 5,79%
Cash Flow / Sales 20,5% 23,5%
Capital Intensity (Assets / Sales) 1,51x 1,54x
Financial Leverage (Net Debt / EBITDA) 1,49x 1,44x
Price Earning Ratio Help 
The blue ligne is the average P/E ratio (without estimates)
EPS & Dividend